OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 271.47 Million CAD | 286.06% |
| 2022 | 70.32 Million CAD | 58.24% |
| 2021 | 44.44 Million CAD | 7.43% |
| 2020 | 41.36 Million CAD | -2.37% |
| 2019 | 42.36 Million CAD | 163.44% |
| 2018 | 16.08 Million CAD | 100.05% |
| 2017 | 8.03 Million CAD | 97.6% |
| 2016 | 4.06 Million CAD | 63.72% |
| 2015 | 2.48 Million CAD | 3621.89% |
| 2014 | 66.77 Thousand CAD | -82.21% |
| 2013 | 375.24 Thousand CAD | 167.72% |
| 2012 | 140.16 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 22.62 Million CAD | -14.98% |
| 2024 Q2 | 23.46 Million CAD | 3.71% |
| 2024 Q3 | 18.09 Million CAD | -18.8% |
| 2023 Q3 | 23.69 Million CAD | 14.79% |
| 2023 FY | 78.59 Million CAD | 11.77% |
| 2023 Q1 | 19.82 Million CAD | -3.48% |
| 2023 Q2 | 20.64 Million CAD | 4.12% |
| 2023 Q4 | 26.61 Million CAD | 12.31% |
| 2022 Q2 | 16.01 Million CAD | 11.76% |
| 2022 Q3 | 19.42 Million CAD | 21.27% |
| 2022 Q4 | 20.54 Million CAD | 5.75% |
| 2022 FY | 70.32 Million CAD | 58.24% |
| 2022 Q1 | 14.33 Million CAD | 4.28% |
| 2021 Q4 | 13.74 Million CAD | 18.29% |
| 2021 Q1 | 9.7 Million CAD | -10.37% |
| 2021 Q2 | 9.36 Million CAD | -3.49% |
| 2021 FY | 44.44 Million CAD | 7.43% |
| 2021 Q3 | 11.62 Million CAD | 24.04% |
| 2020 FY | 41.36 Million CAD | -2.37% |
| 2020 Q1 | 11.04 Million CAD | -31.14% |
| 2020 Q2 | 15.31 Million CAD | 38.71% |
| 2020 Q3 | 8.11 Million CAD | -47.0% |
| 2020 Q4 | 10.83 Million CAD | 33.44% |
| 2019 FY | 42.36 Million CAD | 163.44% |
| 2019 Q2 | 9.72 Million CAD | 76.84% |
| 2019 Q4 | 16.03 Million CAD | 44.32% |
| 2019 Q3 | 11.1 Million CAD | 14.22% |
| 2019 Q1 | 5.5 Million CAD | 29.38% |
| 2018 Q3 | 4.46 Million CAD | 3.78% |
| 2018 Q4 | 4.25 Million CAD | -4.79% |
| 2018 FY | 16.08 Million CAD | 100.05% |
| 2018 Q2 | 4.3 Million CAD | 40.44% |
| 2018 Q1 | 3.06 Million CAD | 4.03% |
| 2017 FY | 8.03 Million CAD | 97.6% |
| 2017 Q4 | 2.94 Million CAD | 72.95% |
| 2017 Q1 | 1.48 Million CAD | 13.55% |
| 2017 Q2 | 1.91 Million CAD | 28.92% |
| 2017 Q3 | 1.7 Million CAD | -10.88% |
| 2016 Q4 | 1.3 Million CAD | 19.73% |
| 2016 FY | 4.06 Million CAD | 63.72% |
| 2016 Q3 | 1.08 Million CAD | 19.99% |
| 2016 Q2 | 908.37 Thousand CAD | 18.71% |
| 2016 Q1 | 765.18 Thousand CAD | 25.01% |
| 2015 Q2 | 731.46 Thousand CAD | 12.95% |
| 2015 Q1 | 647.62 Thousand CAD | 244.69% |
| 2015 FY | 2.48 Million CAD | 3621.89% |
| 2015 Q4 | 612.08 Thousand CAD | 23.91% |
| 2015 Q3 | 493.97 Thousand CAD | -32.47% |
| 2014 Q3 | 25.18 Thousand CAD | 60.49% |
| 2014 Q2 | 15.69 Thousand CAD | 18.71% |
| 2014 Q1 | 13.22 Thousand CAD | 4.32% |
| 2014 Q4 | 187.88 Thousand CAD | 646.03% |
| 2014 FY | 66.77 Thousand CAD | -82.21% |
| 2013 FY | 375.24 Thousand CAD | 167.72% |
| 2013 Q3 | 2962.00 CAD | -94.95% |
| 2013 Q1 | 252.8 Thousand CAD | 315.97% |
| 2013 Q4 | 12.67 Thousand CAD | 327.85% |
| 2013 Q2 | 58.7 Thousand CAD | -76.78% |
| 2012 Q2 | 81.03 Thousand CAD | 1168.18% |
| 2012 Q3 | 43.44 Thousand CAD | -46.39% |
| 2012 Q4 | 60.77 Thousand CAD | 39.9% |
| 2012 FY | 140.16 Thousand CAD | 0.0% |
| 2012 Q1 | 6390.00 CAD | -31.26% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | 9296.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Theratechnologies Inc. | 72.75 Million USD | -273.135% |
| Harrow Health, Inc. | 89.97 Million USD | -201.733% |
| Dynavax Technologies Corporation | 219.14 Million USD | -23.88% |
| Biofrontera Inc. | 39.95 Million USD | -579.391% |
| Cronos Group Inc. | 96.7 Million USD | -180.716% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -2773.998% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -16.954% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -593.377% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2939.43% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -530.749% |
| Radius Health, Inc. | 265.92 Million USD | -2.087% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1861.275% |
| DURECT Corporation | 43.71 Million USD | -521.018% |
| ProPhase Labs, Inc. | 37.85 Million USD | -617.209% |
| Safety Shot Inc | 12.1 Million USD | -2141.823% |
| Phibro Animal Health Corporation | 260.29 Million USD | -4.295% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -8745.267% |
| Alvotech | 285.43 Million USD | 4.891% |
| Assertio Holdings, Inc. | 368.58 Million USD | 26.346% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 48.682% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1665.825% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1968.486% |
| Procaps Group S.A. | 187.24 Million USD | -44.985% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 53.987% |
| SCYNEXIS, Inc. | 51.84 Million USD | -423.603% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -353.673% |
| Viatris Inc. | 5.96 Billion USD | 95.45% |
| OptiNose, Inc. | 85.1 Million USD | -219.003% |
| SIGA Technologies, Inc. | 22.04 Million USD | -1131.582% |
| Tilray Brands, Inc. | 251.35 Million USD | -8.005% |
| PetIQ, Inc. | 192.72 Million USD | -40.863% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1968.486% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 82.995% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -2689.873% |
| Alimera Sciences, Inc. | 62.64 Million USD | -333.387% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -70.518% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -35504.029% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -4512.6% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 13.579% |
| Journey Medical Corporation | 54.59 Million USD | -397.267% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1424.426% |
| Alpha Teknova, Inc. | 45.85 Million USD | -491.984% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -1182.431% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -453.607% |
| PainReform Ltd. | 9.58 Million USD | -2732.615% |
| Cosmos Health Inc. | 26.18 Million USD | -936.936% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -64.566% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -2663.134% |
| Embecta Corp. | 528.4 Million USD | 48.623% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -6702.017% |
| Talphera, Inc. | 11.99 Million USD | -2163.447% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 16.821% |
| Incannex Healthcare Limited | 30.05 Million USD | -803.33% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1190.166% |
| Shineco, Inc. | 17.94 Million USD | -1412.577% |
| Procaps Group, S.A. | 199.47 Million USD | -36.095% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -38.521% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -505.248% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 21.288% |
| Alvotech | 285.43 Million USD | 4.891% |
| Hempacco Co., Inc. | 7.59 Million USD | -3473.747% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -92.929% |
| Bright Green Corporation | 8.25 Million USD | -3189.496% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 0.154% |
| Kamada Ltd. | 45.42 Million USD | -497.627% |
| Indivior PLC | 911 Million USD | 70.2% |
| Evoke Pharma, Inc. | 12.4 Million USD | -2087.637% |
| Flora Growth Corp. | 10.57 Million USD | -2466.196% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1190.166% |
| Evolus, Inc. | 189.75 Million USD | -43.065% |
| HUTCHMED (China) Limited | 436.23 Million USD | 37.767% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -76.131% |
| Akanda Corp. | 3.48 Million USD | -7693.232% |